Safety First: Considerations for Emerging Modalities and Adjunct Therapies


Patient radiation safety is extremely important—but what about modality and adjunctive therapy safety? In this session, you’ll explore different types of combination PET imaging and get familiar with PETCT and the newer PETMR imaging procedure. You’ll also hear from experts about patient safety considerations of common adjunct therapies and significant drug interactions in nuclear medicine.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Describe the emerging modality of PETMR and how it compares to the current PETCT imaging process.
  2. Discuss patient and provider safety of emerging modality of PETMER.
  3. Explain the patient safety considerations of adjunct therapies (gadolinium, morphine, diphenhydramine, adenosine, Lexiscan, and DATScan).
  4. Identify other drug interactions with merging modality of PETMER.

Joint Providership

This activity is approved for Board Certified Nuclear Pharmacist (BCNP) recertification credits.

Eric Smith, PharmD, MS, BCNP
Associate Professor of Radiology and Pharmacy
University of North Carolina
Guofan Xu, MD,PhD
Assistant Professor
MD Anderson Cancer Center
Learning Level: Level 2
Track: Nuclear Pharmacy
Session Time Slot(s): 
Friday, March 22
11:30 AM - 1:30 PM
Washington State Convention Center - Room 615-617
ACPE Pharmacist: 0202-0000-19-017-L05-P
CEUs Pharmacist: .2
Activity Type: